Exosome Therapy Market, Distribution by Type of Therapeutic (Allogeneic and Autologous), Target Indication (Degenerative Meniscal Injury, Dystrophic Epidermolysis Bullosa, Fistula Perianal and Retinitis Pigmentosa), Therapeutic Area (Dermatological Disorders, Musculoskeletal Disorders, Ophthalmic Diseases and Rectal Disorders), Route of Administration (Fistula Tract, Intra-articular and Intra-ocular) and Geography (North America, Europe, Asia-Pacific and Rest of the World): Industry Trends and Global Forecasts, 2022-2040
The exosome therapy market in healthcare and pharmaceutical industry is expected to reach USD 32 million in 2022 and anticipated to grow at a CAGR of 41.2% during the forecast period 2023-2040.
In recent years, extracellular vesicle-based therapies have gained significant traction in the medical field, attracting considerable attention from industry stakeholders due to their promising applications across various medical conditions. This heightened interest primarily arises from their precise targeting capabilities, facilitation of tissue regeneration, and their potential to alleviate inflammation and chronic pain. Exosomes, a specific type of membrane-bound extracellular vesicles, have particularly garnered attention due to their manifold advantages, leading to extensive research across disease diagnosis, drug delivery, and therapeutic interventions. This growing body of research has prompted both industry and non-industry entities to delve into developing exosome-based therapeutics, with some progressing through clinical trials. Moreover, the COVID-19 pandemic has notably accelerated the exploration of exosome therapy, evident in the increased submissions of investigational new drug (IND) applications targeting COVID-19 complexities and associated complications.
A recent comprehensive review encompassing over 200 studies evaluating mesenchymal stem cell (MSC) derived exosomes for preclinical use revealed that these exosomes demonstrated favorable outcomes in more than 70% of the conducted studies. This substantiates the efficacy and potential of MSC-derived exosomes across diverse therapeutic modalities, further highlighting their importance in advancing medical interventions.
Report Coverage
In recent years, extracellular vesicle-based therapies have gained significant traction in the medical field, attracting considerable attention from industry stakeholders due to their promising applications across various medical conditions. This heightened interest primarily arises from their precise targeting capabilities, facilitation of tissue regeneration, and their potential to alleviate inflammation and chronic pain. Exosomes, a specific type of membrane-bound extracellular vesicles, have particularly garnered attention due to their manifold advantages, leading to extensive research across disease diagnosis, drug delivery, and therapeutic interventions. This growing body of research has prompted both industry and non-industry entities to delve into developing exosome-based therapeutics, with some progressing through clinical trials. Moreover, the COVID-19 pandemic has notably accelerated the exploration of exosome therapy, evident in the increased submissions of investigational new drug (IND) applications targeting COVID-19 complexities and associated complications.
A recent comprehensive review encompassing over 200 studies evaluating mesenchymal stem cell (MSC) derived exosomes for preclinical use revealed that these exosomes demonstrated favorable outcomes in more than 70% of the conducted studies. This substantiates the efficacy and potential of MSC-derived exosomes across diverse therapeutic modalities, further highlighting their importance in advancing medical interventions.
Report Coverage
- The analysis focuses on the exosome therapy market, considering the types of therapy, target indications, therapeutic areas, route of administration, and geographical distribution.
- Examination of factors, including drivers, restraints, opportunities, and challenges, impacting market growth is conducted within the report.
- Evaluation of potential advantages and barriers within the market landscape is provided, along with insights into the competitive environment among key market players.
- Revenue forecasts for market segments are projected across four major regions.
- Detailed explanation of exosomes, encompassing various extracellular vesicle types, their origin, secretion, membrane composition, developmental process, and therapeutic applications. Included are discussions on advantages, risks associated with exosome therapy, and future prospects.
- Assessment based on development phases, technology platforms, payload types, target disease indications, therapeutic areas, biological targets, administration routes, therapy types, companies involved, establishment year, size, and headquarters.
- Comprehensive profiles of major exosome therapy companies, focusing on their pipeline, financial data, product portfolio, recent developments, and future outlook.
- Detailed information on leading exosome therapies in advanced development phases, covering product portfolio, clinical trial details, phase, locations, patient enrollment, and trial duration.
- Examination of completed and ongoing clinical trials related to exosome therapeutics, based on trial status, registration year, sponsors, study designs, patient enrollment, trends, participant demographics, and trial locations.
- In-depth analysis of grants awarded to research institutes for exosome therapeutic projects from 2017-2022, focusing on funding details, grant purposes, recipient organizations, and emerging focus areas.
- Analysis of events attended by exosome therapy developers, encompassing event details, locations, participant demographics, active organizers, industry involvement, participant designations, and speakers.
- Examination of partnerships established since 2017, covering research agreements, licensing, manufacturing, development/commercialization deals, mergers/acquisitions in the exosome therapy industry.
- Analysis of investments made in exosome therapeutic companies since 2017, including grants, financing types, IPOs, offerings, debt financing, equity, and funding details.
- Evaluation of start-ups engaged in exosome therapeutics based on pipeline strength, maturity, financial backing, investor count, partnerships, and start-up health indexing.
- A case study on companies offering exosome development and manufacturing services, covering service types, isolation, characterization, purification methods, manufacturing processes, scalability, and scale of operation.
- Examination of exosome therapeutics that did not progress to later clinical stages, based on discontinuation status, target diseases, administration routes, and sponsorship type.
- Coya Therapeutics
- Evox Therapeutics
- Curexsys
- EV Therapeutics
- SHIFTBIO
1. PREFACE
1.1. Scope of the Report
1.2 Market Segmentation
1.3. Research Methodology
1.4. Key Questions Answered
1.5. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Overview of Exosomes
3.1.1. Types of Extracellular Vesicles
3.1.1. Potential Sources of Exosomes
3.2. Exosome Biogenesis
3.2.1. Exosome Formation and Development Process
3.2.2. Secretion of Exosomes
3.3. Applications of Exosomes
3.4. Mechanism of Exosome Therapy
3.4.1. Exosome Drug Therapy
3.4.2. Exosome RNAi Therapy
3.4.3. Exosome Immunotherapy
3.5. Advantages of Exosome Therapy
3.6. Risks and Future Perspectives Associated with Exosome Therapeutics
4. EXOSOME THERAPEUTICS: MARKET LANDSCAPE
4.1. Analysis Methodology and Key Parameters
4.2. Exosome Therapeutics Market Landscape
4.2.1. Analysis by Phase of Development
4.2.2. Analysis by Technology Platform
4.2.3. Analysis by Type of Payload
4.2.4. Analysis by Derived Source
4.2.5. Analysis by Target Disease Indication(s)
4.2.6. Analysis by Therapeutic Area
4.2.7. Analysis by Phase of Development and Therapeutic Area
4.2.8. Analysis by Therapeutic Area and Route of Administration
4.2.9. Analysis by Route of Administration
4.2.10 Analysis by Area of Application
4.2.11. Analysis by Type of Therapy
4.2.12. Analysis by Dosing Frequency
4.2.13. Analysis by Type of Therapy (By Method of Composition)
4.2.14. Analysis by Line of Treatment
4.3. Exosome Therapy Developers
4.3.1. Analysis by Year of Establishment
4.3.2. Analysis by Company Size
4.3.3. Analysis by Location of Headquarters
4.3.4. Most Active Players: Analysis by Number of Therapeutics
5. EXOSOME THERAPY : COMPANY PROFILES
5.1. Coya Therapeutics
5.1.1. Company Overview
5.1.2. Product Portfolio
5.1.3. Recent Developments and Future Outlook
5.2. Evox Therapeutics
5.2.1. Company Overview
5.2.2. Product Portfolio
5.2.3. Recent Developments and Future Outlook
5.3. Curexsys
5.3.1. Company Overview
5.3.2. Product Portfolio
5.3.3. Recent Developments and Future Outlook
5.4. EV Therapeutics
5.4.1. Company Overview
5.4.2. Product Portfolio
5.4.3. Recent Developments and Future Outlook
5.5. SHIFTBIO
5.5.1. Company Overview
5.5.2. Product Portfolio
5.5.3. Recent Developments and Future Outlook
6. EXOSOME THERAPY: DRUG PROFILES
6.1. AEGLE Therapeutics
6.1.1. Company Overview
6.1.2. AGLE-102: Product Portfolio
6.1.2.1. AGLE-102: Clinical Trial Information
6.1.3. Recent Developments and Future Outlook
6.2. AVEM Healthcare
6.2.1. Company Overview
6.2.2. Ardoxso: Product Portfolio
6.2.2.1. Ardoxso: Clinical Trial Information
6.2.3. Recent Developments and Future Outlook
6.3. Cellular Biomedicine Group
6.3.1. Company Overview
6.3.2. Financial Information
6.3.3. haMPC-Exos: Product Portfolio
6.3.3.1. haMPC-Exos: Clinical Trial Information
6.3.4. hMSC-Exos: Product Portfolio
6.3.4.1. hMSC-Exos: Clinical Trial Information
6.3.5. Undisclosed Drug 1: Product Portfolio
6.3.5.1. Undisclosed Drug 1: Clinical Trial Information
6.3.6. Recent Developments and Future Outlook
6.4. OBCTCD24
6.4.1. Company Overview
6.4.2. CovenD24: Product Portfolio
6.4.2.1. CovenD24: Clinical Trial Information
6.4.3. Recent Developments and Future Outlook
6.5. ReNeuron
6.5.1. Company Overview
6.5.2. Financial Information
6.5.3. Undisclosed Drug 1: Product Portfolio
6.5.3.1. Undisclosed Drug 1: Clinical Trial Information
6.5.4. Recent Developments and Future Outlook
6.6. Stem Cell Medicine
6.6.1. Company Overview
6.6.2. Undisclosed Drug 1: Product Portfolio
6.6.3. Recent Developments and Future Outlook
7. CLINICAL TRIAL ANALYSIS
7.1. Analysis Methodology and Key Parameters
7.2. Exosome Therapeutics: List of Clinical Trials
7.2.1. Analysis by Trial Status
7.2.2. Analysis by Trial Registration Year
7.2.3. Analysis by Sponsor / Collaborator
7.2.4. Analysis by Trial Registration Year and Type of Study
7.2.5. Analysis by Trial Registration Year and Trial Status
7.2.6. Analysis by Annual Number of Patients Enrolled
7.2.7. Analysis by Study Design
7.2.8. Analysis by Age Category
7.2.9. Analysis by Phase of Development and Trial Status
7.2.10. Analysis by Phase of Development and Patients Enrolled
7.2.11. Most Active Industry Players: Analysis by Number of Registered Trials
7.2.12. Most Active Non-Industry Players: Analysis by Number of Registered Trials
7.2.13. Analysis by Trial Location
7.2.14. Analysis by Trial Status and Geography
7.2.15. Analysis by Trial Status, Patients Enrolled and Geography
8. ACADEMIC GRANT ANALYSIS
8.1. Analysis Methodology and Key Parameters
8.2. Exosome Therapeutics: List of Academic Grants
8.3. Analysis by Year of Grants Awarded
8.4. Analysis by Amount Awarded per Year
8.5. Analysis by Type of Funding Institute Center
8.6. Analysis by Support Period
8.7. Analysis by Purpose of Grant
8.8. Word Cloud Analysis: Emerging Focus Area
8.9. Analysis by Grant Activity Code
8.10. Analysis by Location of Recipient Organizations
8.11. Popular Recipient Organizations: Analysis by Number of Grants
8.12. Popular Recipient Organizations: Analysis by Amount Awarded
8.13. Analysis by Type of Recipient Organization
8.14. Analysis by Study Section
8.15. Analysis by Type of Grant Application
8.16. Analysis by Funding Institute Center and Support Year
9. GLOBAL EVENT ANALYSIS
9.1. Chapter Overview
9.2. Scope and Methodology
9.3. List of Global Events Related to Exosomes
9.3.1. Analysis by Year of Event
9.3.2. Analysis by Event Platform
9.3.3. Analysis by Type of Event
9.3.4. Analysis by Region
9.3.5. Most Active Organizers: Analysis by Number of Events
9.3.6. Most Active Speakers: Analysis by Number of Events
9.3.7. Most Active Industry Participants: Analysis by Number of Events
9.3.8. Most Active Non-Industry Participants: Analysis by Number of Events
9.3.9. Analysis by Designation of Participant
9.3.10. Analysis by Affiliated Department of Participant
9.3.11. Word Cloud Analysis: Evolutionary Trends in Event Agenda / Key Focus Area
10. PARTNERSHIPS AND COLLABORATIONS
10.1. Chapter Overview
10.2. Partnership Models
10.3. Exosome Therapeutics: List of Partnerships and Collaborations
10.3.1. Analysis by Year of Partnership
10.3.2. Analysis by Type of Partnership
10.3.3. Analysis by Year and Type of Partnership
10.3.4. Analysis by Company and Type of Partnership
10.3.5. Analysis by Type of Technology Platform
10.3.6. Analysis by Type of Partner
10.3.7. Most Active Players: Analysis by Number of Partnerships
10.3.8. Word Cloud Analysis: Emerging Focus Areas
10.3.9. Analysis by Target Disease Indication(s)
10.3.10. Analysis by Therapeutic Area
10.3.11. Analysis by Therapeutic Area and Type of Partnership
10.3.12. Regional Distribution of Partnerships
10.3.13. Distribution by Geography
11. FUNDING AND INVESTMENT ANALYSIS
11.1. Analysis Methodology and Key Parameters
11.2. Type of Funding
11.3. Exosome Therapeutics: List of Funding Instances
11.4. Analysis by Year of Funding
11.5. Analysis by Amount Invested
11.6. Analysis by Type of Funding
11.7. Analysis by Type of Funding and Amount Invested
11.8. Analysis by Purpose of Funding
11.9. Analysis by Target Disease Indication(s)
11.10. Analysis by Therapeutic Area
11.11. Most Active Players: Analysis by Number of Funding Instances
11.12. Most Active Players: Analysis by Amount Raised
11.13. Active Investors: Analysis by Number of Funding Instances
11.14. Distribution by Geography
11.15. Summary of Funding Activity
12. START-UP HEALTH INDEXING
12.1. Analysis Methodology and Key Parameters
12.2. Analysis by Pipeline Strength
12.3. Analysis by Pipeline Maturity
12.4. Analysis by Indication Diversity
12.5. Analysis by Number of Partnerships
12.6. Analysis by Financial Support
12.7. Start-up Health Indexing: Roots Analysis Perspective
12.8. Most Active Start-ups
13. CASE STUDY: EXOSOME DEVELOPMENT AND MANUFACTURING COMPANIES
13.1. Chapter Overview
13.2. Exosome Development and Manufacturing Companies Landscape
13.2.1. Analysis by Year of Establishment
13.2.2. Analysis by Company Size
13.2.3. Analysis by Location of Headquarters
13.2.4. Analysis by Location of Headquarters and Company Size
13.3. Analysis by Type of Service(s) Offered
13.3.1. Analysis by Method of Isolation
13.3.2. Analysis by Method of Purification
13.3.3. Analysis by Method of Characterization
13.3.4. Analysis by Method of Exosome Manufacturing
13.3.5. Analysis by Scale of Operation
13.3.6. Analysis by Scalability
14. DRUG FAILURE ANALYSIS
14.1. Methodology and Key Parameters
14.2. Exosome Therapeutics: List of Failed Drug Candidates
14.2.1. Analysis by Trial Start and Discontinuation Year
14.2.2. Analysis by Trial Status of Discontinuation
14.2.3. Analysis by Target Disease Indication(s)
14.2.4. Analysis by Route of Administration
14.2.5. Analysis by Type of Sponsor
14.2.6. Analysis by Reasons for Drug Failure
14.2.7. Word Cloud Analysis: Emerging Focus Area
15. MARKET SIZING AND OPPORTUNITY ANALYSIS
15.1. Forecast Methodology and Key Assumptions
15.2. Global Exosome Therapy Market, 2029-2040
15.2.1. Exosome Therapy Market for Allogeneic Therapy, 2029-2040 (USD Million)
15.2.2. Exosome Therapy Market for Autologous Therapy, 2029-2040 (USD Million)
15.2.3. Exosome Therapy Market for Degenerative Meniscal Injury, 2031-2040 (USD Million)
15.2.4. Exosome Therapy Market for Dystrophic Epidermolysis Bullosa, 2030-2040 (USD Million)
15.2.5. Exosome Therapy Market for Fistula Perianal, 2029-2040 (USD Million)
15.2.6. Exosome Therapy Market for Retinitis Pigmentosa, 2029-2040 (USD Million)
15.2.7. Exosome Therapy Market for Dermatological Disorders, 2030-2040 (USD Million)
15.2.8. Exosome Therapy Market for Muscoskeletal Disorders, 2031-2040 (USD Million)
15.2.9. Exosome Therapy Market for Ophthalmic Disorders, 2029-2040 (USD Million)
15.2.10. Exosome Therapy Market for Rectal Disorders, 2029-2040 (USD Million)
15.2.11. Fistula Tract Exosome Therapy Market, 2029-2040 (USD Million)
15.2.12. Intra-articular Exosome Therapy Market, 2031-2040 (USD Million)
15.2.13. Intra-ocular Exosome Therapy Market, 2029-2040 (USD Million)
15.2.14. Exosome Therapy Market Geographical Distribution, 2029-2040 (USD Million)
15.2.15. Erciyes University’s Drug: Sales Forecast, 2029-2040 (USD Million)
15.2.16. Synovial Fluid-Derived Mesenchymal Stem Cells: Sales Forecast, 2031-2040 (USD Million)
15.2.17. AGLE-102: Sales Forecast, 2030-2040 (USD Million)
15.2.18. Trehan University of Medical Sciences’ Drug: Sales Forecast, 2029-2040 (USD Million)
15.2.19. ReNeuron’ Drug: Sales Forecast, 2029-2040 (USD Million)
16. EXECUTIVE INSIGHTS
16.1. Capricor Therapeutics
16.1.1. Company Snapshot
16.1.2. Interview Transcript: Xavier Avat, Chief Business Officer
16.2. Exogenus Therapeutics
16.2.1. Company Snapshot
16.2.2. Interview Transcript: Patricia C. Freire, R&D and Innovation Manager
16.3. ILIAS Biologics
16.3.1. Company Snapshot
16.3.2. Interview Transcript: Soonho Song, Chief Business Officer
17. APPENDIX 1: TABULATED DATA
18. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
1.1. Scope of the Report
1.2 Market Segmentation
1.3. Research Methodology
1.4. Key Questions Answered
1.5. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Overview of Exosomes
3.1.1. Types of Extracellular Vesicles
3.1.1. Potential Sources of Exosomes
3.2. Exosome Biogenesis
3.2.1. Exosome Formation and Development Process
3.2.2. Secretion of Exosomes
3.3. Applications of Exosomes
3.4. Mechanism of Exosome Therapy
3.4.1. Exosome Drug Therapy
3.4.2. Exosome RNAi Therapy
3.4.3. Exosome Immunotherapy
3.5. Advantages of Exosome Therapy
3.6. Risks and Future Perspectives Associated with Exosome Therapeutics
4. EXOSOME THERAPEUTICS: MARKET LANDSCAPE
4.1. Analysis Methodology and Key Parameters
4.2. Exosome Therapeutics Market Landscape
4.2.1. Analysis by Phase of Development
4.2.2. Analysis by Technology Platform
4.2.3. Analysis by Type of Payload
4.2.4. Analysis by Derived Source
4.2.5. Analysis by Target Disease Indication(s)
4.2.6. Analysis by Therapeutic Area
4.2.7. Analysis by Phase of Development and Therapeutic Area
4.2.8. Analysis by Therapeutic Area and Route of Administration
4.2.9. Analysis by Route of Administration
4.2.10 Analysis by Area of Application
4.2.11. Analysis by Type of Therapy
4.2.12. Analysis by Dosing Frequency
4.2.13. Analysis by Type of Therapy (By Method of Composition)
4.2.14. Analysis by Line of Treatment
4.3. Exosome Therapy Developers
4.3.1. Analysis by Year of Establishment
4.3.2. Analysis by Company Size
4.3.3. Analysis by Location of Headquarters
4.3.4. Most Active Players: Analysis by Number of Therapeutics
5. EXOSOME THERAPY : COMPANY PROFILES
5.1. Coya Therapeutics
5.1.1. Company Overview
5.1.2. Product Portfolio
5.1.3. Recent Developments and Future Outlook
5.2. Evox Therapeutics
5.2.1. Company Overview
5.2.2. Product Portfolio
5.2.3. Recent Developments and Future Outlook
5.3. Curexsys
5.3.1. Company Overview
5.3.2. Product Portfolio
5.3.3. Recent Developments and Future Outlook
5.4. EV Therapeutics
5.4.1. Company Overview
5.4.2. Product Portfolio
5.4.3. Recent Developments and Future Outlook
5.5. SHIFTBIO
5.5.1. Company Overview
5.5.2. Product Portfolio
5.5.3. Recent Developments and Future Outlook
6. EXOSOME THERAPY: DRUG PROFILES
6.1. AEGLE Therapeutics
6.1.1. Company Overview
6.1.2. AGLE-102: Product Portfolio
6.1.2.1. AGLE-102: Clinical Trial Information
6.1.3. Recent Developments and Future Outlook
6.2. AVEM Healthcare
6.2.1. Company Overview
6.2.2. Ardoxso: Product Portfolio
6.2.2.1. Ardoxso: Clinical Trial Information
6.2.3. Recent Developments and Future Outlook
6.3. Cellular Biomedicine Group
6.3.1. Company Overview
6.3.2. Financial Information
6.3.3. haMPC-Exos: Product Portfolio
6.3.3.1. haMPC-Exos: Clinical Trial Information
6.3.4. hMSC-Exos: Product Portfolio
6.3.4.1. hMSC-Exos: Clinical Trial Information
6.3.5. Undisclosed Drug 1: Product Portfolio
6.3.5.1. Undisclosed Drug 1: Clinical Trial Information
6.3.6. Recent Developments and Future Outlook
6.4. OBCTCD24
6.4.1. Company Overview
6.4.2. CovenD24: Product Portfolio
6.4.2.1. CovenD24: Clinical Trial Information
6.4.3. Recent Developments and Future Outlook
6.5. ReNeuron
6.5.1. Company Overview
6.5.2. Financial Information
6.5.3. Undisclosed Drug 1: Product Portfolio
6.5.3.1. Undisclosed Drug 1: Clinical Trial Information
6.5.4. Recent Developments and Future Outlook
6.6. Stem Cell Medicine
6.6.1. Company Overview
6.6.2. Undisclosed Drug 1: Product Portfolio
6.6.3. Recent Developments and Future Outlook
7. CLINICAL TRIAL ANALYSIS
7.1. Analysis Methodology and Key Parameters
7.2. Exosome Therapeutics: List of Clinical Trials
7.2.1. Analysis by Trial Status
7.2.2. Analysis by Trial Registration Year
7.2.3. Analysis by Sponsor / Collaborator
7.2.4. Analysis by Trial Registration Year and Type of Study
7.2.5. Analysis by Trial Registration Year and Trial Status
7.2.6. Analysis by Annual Number of Patients Enrolled
7.2.7. Analysis by Study Design
7.2.8. Analysis by Age Category
7.2.9. Analysis by Phase of Development and Trial Status
7.2.10. Analysis by Phase of Development and Patients Enrolled
7.2.11. Most Active Industry Players: Analysis by Number of Registered Trials
7.2.12. Most Active Non-Industry Players: Analysis by Number of Registered Trials
7.2.13. Analysis by Trial Location
7.2.14. Analysis by Trial Status and Geography
7.2.15. Analysis by Trial Status, Patients Enrolled and Geography
8. ACADEMIC GRANT ANALYSIS
8.1. Analysis Methodology and Key Parameters
8.2. Exosome Therapeutics: List of Academic Grants
8.3. Analysis by Year of Grants Awarded
8.4. Analysis by Amount Awarded per Year
8.5. Analysis by Type of Funding Institute Center
8.6. Analysis by Support Period
8.7. Analysis by Purpose of Grant
8.8. Word Cloud Analysis: Emerging Focus Area
8.9. Analysis by Grant Activity Code
8.10. Analysis by Location of Recipient Organizations
8.11. Popular Recipient Organizations: Analysis by Number of Grants
8.12. Popular Recipient Organizations: Analysis by Amount Awarded
8.13. Analysis by Type of Recipient Organization
8.14. Analysis by Study Section
8.15. Analysis by Type of Grant Application
8.16. Analysis by Funding Institute Center and Support Year
9. GLOBAL EVENT ANALYSIS
9.1. Chapter Overview
9.2. Scope and Methodology
9.3. List of Global Events Related to Exosomes
9.3.1. Analysis by Year of Event
9.3.2. Analysis by Event Platform
9.3.3. Analysis by Type of Event
9.3.4. Analysis by Region
9.3.5. Most Active Organizers: Analysis by Number of Events
9.3.6. Most Active Speakers: Analysis by Number of Events
9.3.7. Most Active Industry Participants: Analysis by Number of Events
9.3.8. Most Active Non-Industry Participants: Analysis by Number of Events
9.3.9. Analysis by Designation of Participant
9.3.10. Analysis by Affiliated Department of Participant
9.3.11. Word Cloud Analysis: Evolutionary Trends in Event Agenda / Key Focus Area
10. PARTNERSHIPS AND COLLABORATIONS
10.1. Chapter Overview
10.2. Partnership Models
10.3. Exosome Therapeutics: List of Partnerships and Collaborations
10.3.1. Analysis by Year of Partnership
10.3.2. Analysis by Type of Partnership
10.3.3. Analysis by Year and Type of Partnership
10.3.4. Analysis by Company and Type of Partnership
10.3.5. Analysis by Type of Technology Platform
10.3.6. Analysis by Type of Partner
10.3.7. Most Active Players: Analysis by Number of Partnerships
10.3.8. Word Cloud Analysis: Emerging Focus Areas
10.3.9. Analysis by Target Disease Indication(s)
10.3.10. Analysis by Therapeutic Area
10.3.11. Analysis by Therapeutic Area and Type of Partnership
10.3.12. Regional Distribution of Partnerships
10.3.13. Distribution by Geography
11. FUNDING AND INVESTMENT ANALYSIS
11.1. Analysis Methodology and Key Parameters
11.2. Type of Funding
11.3. Exosome Therapeutics: List of Funding Instances
11.4. Analysis by Year of Funding
11.5. Analysis by Amount Invested
11.6. Analysis by Type of Funding
11.7. Analysis by Type of Funding and Amount Invested
11.8. Analysis by Purpose of Funding
11.9. Analysis by Target Disease Indication(s)
11.10. Analysis by Therapeutic Area
11.11. Most Active Players: Analysis by Number of Funding Instances
11.12. Most Active Players: Analysis by Amount Raised
11.13. Active Investors: Analysis by Number of Funding Instances
11.14. Distribution by Geography
11.15. Summary of Funding Activity
12. START-UP HEALTH INDEXING
12.1. Analysis Methodology and Key Parameters
12.2. Analysis by Pipeline Strength
12.3. Analysis by Pipeline Maturity
12.4. Analysis by Indication Diversity
12.5. Analysis by Number of Partnerships
12.6. Analysis by Financial Support
12.7. Start-up Health Indexing: Roots Analysis Perspective
12.8. Most Active Start-ups
13. CASE STUDY: EXOSOME DEVELOPMENT AND MANUFACTURING COMPANIES
13.1. Chapter Overview
13.2. Exosome Development and Manufacturing Companies Landscape
13.2.1. Analysis by Year of Establishment
13.2.2. Analysis by Company Size
13.2.3. Analysis by Location of Headquarters
13.2.4. Analysis by Location of Headquarters and Company Size
13.3. Analysis by Type of Service(s) Offered
13.3.1. Analysis by Method of Isolation
13.3.2. Analysis by Method of Purification
13.3.3. Analysis by Method of Characterization
13.3.4. Analysis by Method of Exosome Manufacturing
13.3.5. Analysis by Scale of Operation
13.3.6. Analysis by Scalability
14. DRUG FAILURE ANALYSIS
14.1. Methodology and Key Parameters
14.2. Exosome Therapeutics: List of Failed Drug Candidates
14.2.1. Analysis by Trial Start and Discontinuation Year
14.2.2. Analysis by Trial Status of Discontinuation
14.2.3. Analysis by Target Disease Indication(s)
14.2.4. Analysis by Route of Administration
14.2.5. Analysis by Type of Sponsor
14.2.6. Analysis by Reasons for Drug Failure
14.2.7. Word Cloud Analysis: Emerging Focus Area
15. MARKET SIZING AND OPPORTUNITY ANALYSIS
15.1. Forecast Methodology and Key Assumptions
15.2. Global Exosome Therapy Market, 2029-2040
15.2.1. Exosome Therapy Market for Allogeneic Therapy, 2029-2040 (USD Million)
15.2.2. Exosome Therapy Market for Autologous Therapy, 2029-2040 (USD Million)
15.2.3. Exosome Therapy Market for Degenerative Meniscal Injury, 2031-2040 (USD Million)
15.2.4. Exosome Therapy Market for Dystrophic Epidermolysis Bullosa, 2030-2040 (USD Million)
15.2.5. Exosome Therapy Market for Fistula Perianal, 2029-2040 (USD Million)
15.2.6. Exosome Therapy Market for Retinitis Pigmentosa, 2029-2040 (USD Million)
15.2.7. Exosome Therapy Market for Dermatological Disorders, 2030-2040 (USD Million)
15.2.8. Exosome Therapy Market for Muscoskeletal Disorders, 2031-2040 (USD Million)
15.2.9. Exosome Therapy Market for Ophthalmic Disorders, 2029-2040 (USD Million)
15.2.10. Exosome Therapy Market for Rectal Disorders, 2029-2040 (USD Million)
15.2.11. Fistula Tract Exosome Therapy Market, 2029-2040 (USD Million)
15.2.12. Intra-articular Exosome Therapy Market, 2031-2040 (USD Million)
15.2.13. Intra-ocular Exosome Therapy Market, 2029-2040 (USD Million)
15.2.14. Exosome Therapy Market Geographical Distribution, 2029-2040 (USD Million)
15.2.15. Erciyes University’s Drug: Sales Forecast, 2029-2040 (USD Million)
15.2.16. Synovial Fluid-Derived Mesenchymal Stem Cells: Sales Forecast, 2031-2040 (USD Million)
15.2.17. AGLE-102: Sales Forecast, 2030-2040 (USD Million)
15.2.18. Trehan University of Medical Sciences’ Drug: Sales Forecast, 2029-2040 (USD Million)
15.2.19. ReNeuron’ Drug: Sales Forecast, 2029-2040 (USD Million)
16. EXECUTIVE INSIGHTS
16.1. Capricor Therapeutics
16.1.1. Company Snapshot
16.1.2. Interview Transcript: Xavier Avat, Chief Business Officer
16.2. Exogenus Therapeutics
16.2.1. Company Snapshot
16.2.2. Interview Transcript: Patricia C. Freire, R&D and Innovation Manager
16.3. ILIAS Biologics
16.3.1. Company Snapshot
16.3.2. Interview Transcript: Soonho Song, Chief Business Officer
17. APPENDIX 1: TABULATED DATA
18. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
